Know Cancer

forgot password

Biomarkers Study in Pancreatic Cancer

20 Years
75 Years
Open (Enrolling by invite only)
Biomarkers Study in Pancreatic Cancer

Thank you

Trial Information

Biomarkers Study in Pancreatic Cancer

We expect to collect tissue samples from 270 pancreatic cancer patients of any stages. Since
the enrollment criteria are not limited to new patients, we expect to enroll 67 patients a
year. The patient enrollment will be completed in 4 years. Clinical follow-up will be
completed in another one year. Data analysis and correlation study may be finished in the
end of 5th year of this study.

Inclusion Criteria:

1. Patients enrolled to TCOG 3207 study: A Randomized Phase III Study of Adjuvant
Gemcitabine versus Gemcitabine Plus Concurrent Chemoradiation in Pancreatic Cancer
Underwent Curative Intent (R0 / R1) Resection.

2. Patients who were not eligible for TCOG 3207 study but received surgery or biopsy for
pancreatic cancer.

3. Patients have to sign informed consent for tissue specimen collection, according to
the regulation of DOH.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

Yi-Ming Shyr, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Taipei Veterans General Hospital,Taiwan


Department of Health : Taiwan

Study ID:




Start Date:

September 2012

Completion Date:

December 2017

Related Keywords:

  • Biomarkers Study in Pancreatic Cancer
  • Biomarkers study
  • Pancreatic Neoplasms